Patents by Inventor Eun-Bee Cho
Eun-Bee Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240166735Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: July 11, 2023Publication date: May 23, 2024Applicant: Neuracle Science Co., Ltd.Inventors: Jae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
-
Publication number: 20240088440Abstract: A lithium secondary battery includes a negative electrode, a positive electrode positioned opposite to the negative electrode, a separator disposed between the negative electrode and the positive electrode, and a non-aqueous electrolyte, wherein the negative electrode includes a silicon-based active material, the silicon-based active material comprises a compound represented by SiOx, wherein 0?x<2, the non-aqueous electrolyte includes a lithium salt, an organic solvent, and an additive, the additive includes a first additive and a second additive, the first additive includes a coumarin-based compound represented by Formula 1, and the second additive includes at least one of lithium fluoromalonato(difluoro)borate (LiFMDFB), lithium difluoro(oxalato)borate (LiDFOB), lithium difluorophosphate (LiDFP), or lithium difluorobis-(oxalate)phosphate (LiDFOP): wherein R and n are described herein.Type: ApplicationFiled: August 17, 2023Publication date: March 14, 2024Applicant: LG Energy Solution, Ltd.Inventors: Yoon Gyo Cho, Chul Haeng Lee, Kyung Mi Lee, Jung Min Lee, Eun Bee Kim, Su Hyeon Ji, Chul Eun Yeom, Jung Gu Han
-
Publication number: 20230348584Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.Type: ApplicationFiled: January 23, 2023Publication date: November 2, 2023Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Eun Bee CHO, Dong Sik KIM, Jae-Keun LEE, Soon-gu KWON, Jae Young SEONG, Juwon SHIM, Tae Woo KIM, Shin-hyuk KANG
-
Patent number: 11739141Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: March 3, 2020Date of Patent: August 29, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Publication number: 20230187741Abstract: A rechargeable battery according to an embodiment of the present invention includes: a first case receiving an electrode assembly and having a first opening; a second case having a second opening smaller than the first opening and coupled to the inner surface of the first case with the outer surface while covering the electrode assembly; an insulating material interposed between the first case and the second case to form an electrically insulating state; a plurality of protruded parts protruded onto the outer surface of the second case; and a plurality of accommodating parts formed in the first case and coupled to the protruded part, wherein the first case and the second case are concluded to form a closed state when the protruded part is coupled to the accommodating part.Type: ApplicationFiled: January 6, 2021Publication date: June 15, 2023Inventors: Wonwook CHO, Heejung KO, Eun-Bee CHO
-
Publication number: 20230104540Abstract: The present disclosure relates to a method of treating a disease or disorder associated with an abnormality in CNS function. Also provided is a method for diagnosing and/or identifying a subject having an abnormality in CNS function. FAM19A1 antagonists that can be used with the present disclosures are also provided.Type: ApplicationFiled: March 2, 2021Publication date: April 6, 2023Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON, Nui HA, Jae Young SEONG, Jong Ik HWANG, Hyo Jung YONG, Eun Bee CHO
-
Patent number: 11560425Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.Type: GrantFiled: June 27, 2018Date of Patent: January 24, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Eun Bee Cho, Dong Sik Kim, Jae-Keun Lee, Soon-gu Kwon, Jae Young Seong, Juwon Shim, Tae Woo Kim, Shin-hyuk Kang
-
Publication number: 20220372122Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: ApplicationFiled: April 18, 2022Publication date: November 24, 2022Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol KIM, Jae Young SEONG, Jong Ik HWANG, Eun Bee CHO, Junho CHUNG, Junyeong JIN, Tae Young YUNE, Jee Youn LEE
-
Patent number: 11332521Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: GrantFiled: November 7, 2017Date of Patent: May 17, 2022Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
-
Publication number: 20200270337Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: March 3, 2020Publication date: August 27, 2020Applicant: Neuracle Science Co., Ltd.Inventors: Jae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
-
Publication number: 20200223914Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.Type: ApplicationFiled: June 27, 2018Publication date: July 16, 2020Applicant: Neuracle Science Co., Ltd.Inventors: Bongcheol KIM, Eun Bee CHO, Dong Sik KIM, Jae-Keun LEE, Soon-gu KWON, Jae Young SEONG, Juwon SHIM, Tae Woo KIM, Shin-hyuk KANG
-
Patent number: 10640557Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: January 11, 2017Date of Patent: May 5, 2020Assignee: Neuracle Sceince, Inc.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Publication number: 20190300599Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: ApplicationFiled: November 7, 2017Publication date: October 3, 2019Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol KIM, Jae Young SEONG, Jong Ik HWANG, Eun Bee CHO, Junho CHUNG, Junyeong JIN, Tae Young YUNE, Jee Youn LEE
-
Publication number: 20170121401Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: January 11, 2017Publication date: May 4, 2017Inventors: Jae Young SEONG, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Patent number: 9579398Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: February 15, 2013Date of Patent: February 28, 2017Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-ki Kim
-
Publication number: 20150118230Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: February 15, 2013Publication date: April 30, 2015Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Patent number: 8999543Abstract: The present invention relates to a rechargeable battery that can use a negative electrode active material having a high volume expansion rate by receiving volume variation of an electrode assembly in a case. The rechargeable battery according to the present invention includes i) an electrode assembly including a positive electrode plate, a negative electrode plate, and a separator that are wound in a jelly roll shape to have a flat portion and curved portions disposed at both sides of the flat portion, ii) a case for receiving the electrode assembly, and iii) a cap assembly combined with the case to close and seal the case and that is electrically connected to the electrode assembly. When a direction that is perpendicular to a surface of the separator disposed in the flat portion is set to a first direction, the thickness of the flat portion measured along the first direction is smaller than the maximum thickness of the curved portion measured along the first direction.Type: GrantFiled: September 1, 2010Date of Patent: April 7, 2015Assignee: Samsung SDI Co., Ltd.Inventor: Eun-Bee Cho
-
Patent number: D686590Type: GrantFiled: October 11, 2012Date of Patent: July 23, 2013Assignee: Samsung Electronics Co., Ltd.Inventor: Eun-Bee Cho
-
Patent number: D688645Type: GrantFiled: October 18, 2012Date of Patent: August 27, 2013Assignee: Samsung Electronics Co., Ltd.Inventor: Eun-Bee Cho
-
Patent number: D699208Type: GrantFiled: August 24, 2012Date of Patent: February 11, 2014Assignee: Samsung Electronics Co., Ltd.Inventor: Eun-Bee Cho